Overcoming Challenges in Antibacterial Drug Discovery and Development : Market Research Report

Overcoming Challenges in Antibacterial Drug Discovery and Development

Published: Mar. 30, 2007 - 39 Pages

The price of this report has been reduced due to its age. The original price was $2,025 for PDF.

Executive Summary: Strategic Considerations; Stakeholder Implications
Highly Mature Markets
Drivers in Antibacterial Drug Discovery: Antibiotic Resistance and Different Resistance Mechanisms; Emerging Pathogens and Diseases; Community Setting; Hospital Settings; Biodefense Initiatives
New Approaches to Discovering Antibacterial Agents: The Impact of Genomics; Successful Genomics Endeavors; Genomics-Driven, High-Throughput Screening; Novel Targets and Approaches; Novel Antibodies; Topical Antibacterial Agents; Quorum Sensing Antagonists; Peptide Deformylase (PDF) Inhibitors; Novel Beta-Lactams; Peptides and Peptide Mimetics
Spectrum Executive Commentary: Quorum Sensing: Preventing Bacteria From Behaving Badly: Fatty Acid Biosynthesis Inhibitors; Combination Therapies; Oxazolidinone-Quinolone Hybrid; Effl ux Pump Inhibitors (EPIs); Beta-Lactamase Inhibitors
Significant Clinical Challenges: The Conundrum of Spectrum vs. Indication; Regulatory Hurdles
Business Strategies: Drug Discovery; Marketing and Sales Alliances; Big Pharma’s Outlicensing Programs; Mergers & Acquisitions (M&As); Strategies for Niche Markets
Company Profiles: Oscient Pharmaceuticals; Cubist Pharmaceuticals; Replidyne; Novexel
Outlook: Commercial Opportunity; Development Incentives; Diagnostic Testing Incentives; Regulatory Incentives; Financial and Legislative Incentives
Tables:: 1. Mechanisms of Bacterial Resistance to Select Antibiotic Drug Classes; 2. Companies Involved in Antibacterial Drug Discovery Programs: Key Products; 3. Antibacterial Research and License Agreements, 2005-2007; 4. Key Patent and Exclusivity Expiries of Drugs Used to Treat Bacterial Infections
Figures:: 1. Market Tenure of Antibiotic Classes; 2. Mechanisms of Transferring or Spreading Drug Resistance; 3. Mechanisms of Antibiotic Drug Resistance; 4. Development Timeline for Antibacterial Drugs; 5. Top Worldwide Antibacterial Franchises, 2005; 6. Blockbusters and Best-Selling Antibacterials Worldwide, 2005; 7. Relative Size of Smaller Pharmaceutical and Biotech Companies Involved in Antibacterial Drug Development; A. Selected Quorum-Sensing Antagonists

Abstract

The antibacterial market is highly mature, yet there is a compelling need to discover new antibacterials to combat the escalating threats of drug resistance, the threats posed by new and reemerging pathogens, and bioterrorism threats. In recent years, unmet medical needs and the advent of genomics technologies renewed companies’ interest concerning antibacterial drug discovery. Smaller pharmaceutical companies and biotech companies have filled the void created when big pharma abandoned the arena and are now developing more than 80% of today’s emerging antibacterial agents.

Get the Answers You Need to Shape Your Strategy

Some approaches to antibacterial drug development are more notable advances than others. What approaches are these and which approaches should produce drugs that command higher prices than conventional antibiotics?
Several factors are driving today’s antibacterial drug discovery efforts. What factors are most relevant to fi ghting pathogens in community settings? What factors are most relevant to fighting pathogens in hospital settings?
Although big pharma has largely abandoned the development of antibacterial agents, it has maintained a stake in the antibacterial market through a variety of marketing and sales alliances. Which current partnerships between big pharma and smaller pharmaceutical companies show the greatest promise?
Several antibacterial blockbusters were on the market in 2005, yet most pharmaceutical companies had a sparse antibacterial drug portfolio. Which company is an exception to the rule that the antibacterial drug portfolio of big pharma companies typically is dominated by a blockbuster agent? What lessons can be learned from this company’s strategy of developing several moderately successful drugs?
Despite fi nancial and regulatory hurdles impeding the development of antibacterial agents, commercial opportunities to develop antibacterials that are effective against drug-resistant pathogens, especially in hospital settings, still remain. What are these opportunities? What incentives would bring more players into antibacterial drug discovery and development?

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Overcoming Challenges in Antibacterial Drug Discovery and Development

Table of Contents

Abstract